Dose escalation in extracranial stereotactic ablative radiotherapy (DESTROY-1): A multiarm Phase I trial.

Francesco DeodatoGabriella MacchiaSavino CillaAnna IaniroGiuseppina SallustioSilvia CammelliMilly BuwengeGian Carlo MattiucciVincenzo ValentiniAlessio G Morganti

Published in: The British journal of radiology (2018)

In a prospective dose-escalation trial, the MTD of 50 Gy/10 Gy fraction and 35 Gy/7 Gy fraction were defined for primary and metastatic lesions and as boost after prior RT dose ≤50 Gy, respectively.

Keyphrases

open label
study protocol
phase iii
clinical trial
phase ii
squamous cell carcinoma
small cell lung cancer
early stage
radiation therapy
randomized controlled trial
radiation induced
double blind